CRPL is a subsidiary of TCG Lifesciences, a provider of drug discovery and development research services company.
CTA CEO Marcus Clark said they expect that this collaboration will be advantageous to their clients as it allows for a seamless transition from a Phase I centre to a network that includes sites in both India and Australia.
"With both CTA and Clininvent collaborating to offer trial design, ethics and governance management, site initiation and monitoring there will be significant efficiencies achieved for client companies," Clark said.